Scarica l'app Stockscreener
28.86
86.43%
13.38
Pre-mercato:
27.88
-0.98
-3.40%
Precedente Chiudi:
$15.48
Aprire:
$22.64
Volume 24 ore:
15.70M
Relative Volume:
15.24
Capitalizzazione di mercato:
$1.91B
Reddito:
-
Utile/perdita netta:
$-119.67M
Rapporto P/E:
-10.57
EPS:
-2.73
Flusso di cassa netto:
$-97.30M
1 W Prestazione:
+91.00%
1M Prestazione:
+111.20%
6M Prestazione:
+215.75%
1 anno Prestazione:
+132.55%
Intervallo 1D:
$22.00
$30.14
Intervallo di 1 settimana:
$14.94
$30.14
Portata 52W:
$8.241
$30.14
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER ROAD, RADNOR
Confronta MLYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
28.86 | 1.03B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Is Mineralys Therapeutics Inc. still worth holding after the dip2025 Trade Ideas & Weekly Top Performers Watchlists - Newser
How to interpret RSI for Mineralys Therapeutics Inc. stockQuarterly Market Review & Low Volatility Stock Recommendations - Newser
Q&A with Jon Congleton, CEO of Mineralys Therapeutics - The Pharma Letter
Mineralys Therapeutics Prices $250 Million Notes Offering - MarketScreener
What MACD and RSI say about Mineralys Therapeutics Inc.Earnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
How sentiment analysis helps forecast Mineralys Therapeutics Inc.July 2025 Reactions & Low Risk Entry Point Guides - Newser
Published on: 2025-09-03 02:21:26 - Newser
How moving averages guide Mineralys Therapeutics Inc. tradingEarnings Overview Report & Safe Entry Point Identification - Newser
Key metrics from Mineralys Therapeutics Inc.’s quarterly dataJuly 2025 Drop Watch & Stepwise Trade Execution Plans - Newser
Chart overlay techniques for tracking Mineralys Therapeutics Inc.Quarterly Market Summary & Daily Price Action Insights - Newser
Using RSI to spot recovery in Mineralys Therapeutics Inc.July 2025 Patterns & Technical Confirmation Trade Alerts - Newser
Mineralys Therapeutics' $250M Upsized Equity Raise: A Strategic Inflection Point for Hypertension Innovation - AInvest
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Published on: 2025-09-03 00:47:22 - Newser
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
$250 Million Stock Offering: Hypertension Drug Developer Mineralys Prices Upsized Public Share Sale - Stock Titan
Mineralys Therapeutics Prices Upsized Public Offering Of 9.80 Mln At $25.50/shr - Nasdaq
Mineralys Therapeutics announces pricing of upsized $250.0 million underwritten public offering of common stock - MarketScreener
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire
Does Mineralys Therapeutics Inc. align with a passive investing strategyQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - خودرو بانک
Mineralys Stock Surges 86.43% on $0.43B Trading Volume Ranked 256th in Market Activity as $175M Public Offering Drives Institutional Confidence - AInvest
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
Mineralys Therapeutics announces proposed public offering of common stock - MarketScreener
Mineralys Therapeutics Halts Common Stock Offering - TipRanks
Mineralys Therapeutics down on $175 mln stock offering plans - TradingView
Can volume confirm reversal in Mineralys Therapeutics Inc.Layoff News & Stock Timing and Entry Methods - Newser
Mineralys Therapeutics launches $175 million public stock offering - Investing.com
Mineralys Therapeutics Launches $175 Million Public Share Offering - MarketScreener
Mineralys Therapeutics announces $175M common stock offering - TipRanks
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
$175 Million Stock Offering: Mineralys Therapeutics Seeks Funding for Hypertension Drug Development - Stock Titan
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - MSN
AstraZeneca's Blood Pressure Drug Baxdrostat Shows Positive Trial Results, Boosting Mineralys Therapeutics Shares by 85% - AInvest
Short interest data insights for Mineralys Therapeutics Inc.July 2025 Action & AI Enhanced Trading Signals - Newser
Published on: 2025-09-02 10:08:50 - Newser
Mineralys Therapeutics stock hits all-time high at 22.0 USD - Investing.com
What candlestick patterns are forming on Mineralys Therapeutics Inc.2025 Technical Patterns & Safe Capital Preservation Plans - Newser
Mineralys Therapeutics Jumps On Baxdrostat Hypertension Trial Results - RTTNews
Is Mineralys Therapeutics Inc. likely to announce a buybackPrice Action & AI Forecast for Swing Trade Picks - خودرو بانک
Why Did MLYS Soar 15.76%? Wellington Management Boosts Stake - AInvest
Mineralys Therapeutics Inc. stock momentum explained2025 Biggest Moves & Weekly Momentum Stock Picks - Newser
Mineralys Therapeutics Inc. stock trend forecastEarnings Growth Report & Risk Controlled Daily Plans - Newser
Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones - TipRanks
Pattern recognition hints at Mineralys Therapeutics Inc. upsideSell Signal & Daily Growth Stock Investment Tips - Newser
Is now a turning point for Mineralys Therapeutics Inc.July 2025 Recap & Safe Capital Growth Stock Tips - Newser
Published on: 2025-09-01 12:07:19 - Newser
Can a trend reversal in Mineralys Therapeutics Inc. lead to recoveryPortfolio Return Summary & Weekly High Return Stock Opportunities - Newser
Using flow based indicators on Mineralys Therapeutics Inc.Earnings Performance Report & Daily Oversold Stock Bounce Ideas - Newser
Advanced analytics toolkit walkthrough for Mineralys Therapeutics Inc.2025 Big Picture & Technical Entry and Exit Alerts - Newser
Mineralys Therapeutics, Inc. Earnings Call Highlights - TipRanks
analyzing mineralys therapeutics inc. with risk reward ratio charts2025 Investor Takeaways & Low Volatility Stock Recommendations - Newser
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):